Drugs / 225Ac-PSMA-R2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05983198 | Nov 2023 → Mar 2031 expected | prostate cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 225Ac-PSMA-R2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05983198 ↗ |